Venus Medtech (Hangzhou) Inc. (2500.HK) HKSE
1.34
+0.04(+3.08%)
Currency In HKD
- General
- Statistics
- Historical Data
- Profile
- Financials
Venus Medtech (Hangzhou) Inc.
Address
No. 88, Jiangling Road
Hangzhou, 31005
China
Phone
86 57 1877 72180
Website
Sector
Healthcare
Industry
Medical - Devices
Employees
691
First IPO Date
December 10, 2019
Key Executives
| Name | Title | Pay | Year Born |
| Liqiao Ma | Executive Director | 2.04M | 1985 |
| Meirong Liu | VP, Chief Operation Officer & Executive Director | 2.96M | 1976 |
| Hou-Sen Lim MEng. | GM & Executive Director | 3.32M | 1975 |
| Chui Mei Yip | Company Secretary | 0 | N/A |
| Amir Gross | Head of Venus Global Heart Valve Innovation Center | 0 | N/A |
| Christopher Lee Richardson | Head of U.S. Operations | 0 | 1962 |
| Joyce Heo | Director of Sales | 0 | N/A |
| Wai Chiu Wong | Company Secretary | 0 | 1956 |
| Renzheng Ma | VP & Chief Technology Officer | 0 | 1976 |
| Yan Xiao | Secretary of the Board | 0 | 1983 |
| Bing Zhu | Chief Financial Officer | 0 | 1965 |
| Zhu Bing | Chief Financial Officer | 0 | 1965 |
| Shakeel Osman | Head of International Congenital Heart Disease Business | 0 | N/A |
Description
Venus Medtech (Hangzhou) Inc. develops and commercializes transcatheter heart valve medical devices in Mainland China and internationally. The company's products include VenusA-Valve, a transcatheter aortic heart valve replacement (TAVR) product to treat severe aortic stenosis; VenusP-Valve is a transcatheter pulmonary valve system to treat the dysfunction of right ventricular outflow tract; V8/TAV8 balloon aortic valvuloplasty catheter systems; and TriGUARD3, a cerebral embolic protection device for minimizing the risk of brain damage and prevent cerebral embolism during TAVR and other structural heart disease surgeries. It also develops VenusA-Plus and VenusA-Pilot, which are TAVR product candidates; and transcatheter mitral and tricuspid valve replacement products; Liwen RF ablation system for the treatment of hypertrophic cardiomyopathy; and renal denervation for the treatment of hypertension. The company was founded in 2009 and is headquartered in Hangzhou, the People's Republic of China.
